PROP1 mutation screening detected a homozygous deletion of the entire PROP1 in three patients.
PROP1 gene was amplified using PCR primers: Forward (5' ACCTACACACACATTCAGAGAC 3'), Reverse (5' TGGAGCCTATGCTTTCAGC 3'), Forward (5' AAAGACTGGAGCAGCACAGG3'), Reverse (5' GGTGGTGAGATGAGGCCTGT 3'), and Forward (5' GCCTTGTGGAAGAGCTTTACTCC 3'), Reverse (5' CACCATGCATCTGCTTCACCC 3').
PROP1 overexpression in corticotrophinomas: evidence for the role of PROP1 in the maintenance of cells committed to corticotrophic differentiation.
Molecular basis for pituitary dysfunction: Comparison of Prop1 and Pit1 mutant mice.
prop1 stands for that P intends proposition "R believes p being hold at time [t.sub.p]" being hold.
Mutations of
PROP1 are the most frequent genetic defect in non-syndromic combined pituitary hormone insufficiency and are characterized by growth hormone (GH), prolactin, TSH, and gonadotropin deficiency.
The most commonly recognized genetic defects associated with CPHD include mutations within
PROP1, POU1F1, HESX1, LHX3, LHX4, OTX2, GLI2, and SOX3.
HESX1, POU1F1,
PROP1, LHX4, LHX3, and OTX2 genes have been associated with combined pituitary hormone deficiencies to date.
Because of the combination of central hypothyroidism, GH deficiency, low PRL status, and normal pituitary imaging, genetic testing of
PROP1 and POU1F1 was performed, but no mutations were found.